<DOC>
	<DOC>NCT02849132</DOC>
	<brief_summary>Patients who have completed 2-years entecavir-based treatment in Regress Study will receive another 5-years entecavir extension therapy. Patients will be assessed at baseline and every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan; A third liver biopsy will be performed at year 3 in patients who have significant fibrosis at second biopsy. CT and endoscopy will be performed at baseline and year 3.</brief_summary>
	<brief_title>Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects who completed the 2 years of entecavirbased therapy in Regress study; Subjects who are willing to participate the extension study. Any complication of severe heart, lung, kidney, brain, blood diseases or other important systematic diseases; Pregnant women; Subjects who could not compliance with the protocol judged by investigators; Subjects who are not suitable for the study judged by investigators.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>